NCT06684509View on ClinicalTrials.gov

Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2029

Conditions
LeukemiaHodgkin Disease
Interventions
DRUG

Atrovastain

atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months

Trial Locations (1)

71515

Assiut university, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06684509 - Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia | Biotech Hunter | Biotech Hunter